UCB wins FDA ap­provals in plaque pso­ri­a­sis and gMG, un­lock­ing block­buster op­por­tu­ni­ties

UCB’s treat­ment can­di­dates for plaque pso­ri­a­sis and gen­er­al­ized myas­the­nia gravis have both bagged ap­provals in the US, ex­pand­ing cur­rent mar­ket op­por­tu­ni­ties and open­ing up new ones with block­buster po­ten­tial, ac­cord­ing to an­a­lysts.

First off, the Bel­gian drug­mak­er’s Bimzelx, al­so known as bimek­izum­ab, to­day won a long-await­ed FDA ap­proval for mod­er­ate to se­vere plaque pso­ri­a­sis pa­tients who are can­di­dates for sys­temic ther­a­py or pho­tother­a­py. Plaque pso­ri­a­sis af­fects more than 7.5 mil­lion adults in the US, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER